How high is DEGN predicted to rise to Today

DEGN is not currently predicted to rise significantly. Analysts have set an average 12-month price target of $24.17 for Deciphera Pharmaceuticals (DCPH), suggesting a potential downside of 5.54% from the current price. Additionally, the stock has been given a "Hold" consensus rating by ten research firms, with three recommending a buy and seven suggesting a hold. These indicators suggest that while there is some positive sentiment among analysts, the stock is not expected to experience a high rise in the near term.